Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections

Bing Zhai1,2,3, Chen Liao4, Siddharth Jaggavarapu5,6,7,8

  • 1Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China. bing.zhai@siat.ac.cn.

Nature Medicine
|August 2, 2024
PubMed

Insights

Breakthrough fungal infections in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are often caused by Candida parapsilosis heteroresistance to micafungin. Standard tests miss this resistance, impacting treatment effectiveness.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Hematology

Background:

  • Breakthrough fungal infections, particularly invasive candidiasis, pose significant risks in patients receiving antimicrobial prophylaxis during allogeneic hematopoietic cell transplantation (allo-HCT).
  • Candida parapsilosis, a WHO high-priority pathogen, is a frequent cause of invasive candidiasis, and its resistance patterns are critical for patient outcomes.
  • Unexplained antifungal prophylaxis failures in high-risk allo-HCT recipients necessitate investigation into underlying resistance mechanisms.

Purpose of the Study:

  • To investigate the role of micafungin heteroresistance in breakthrough Candida parapsilosis bloodstream infections in patients undergoing allo-HCT.
  • To assess the prevalence of micafungin heteroresistance in C. parapsilosis isolates globally.
  • To develop a novel diagnostic approach for detecting micafungin heteroresistance.

Main Methods:

  • Analysis of 219 clinical C. parapsilosis isolates from diverse geographical regions.
  • Evaluation of standard antimicrobial susceptibility testing methods for their ability to detect micafungin heteroresistance.
  • Development and validation of a machine learning framework utilizing genomic features for heteroresistance prediction.

Main Results:

  • Micafungin heteroresistance, characterized by a low-frequency resistant subpopulation, was identified as a key factor in breakthrough C. parapsilosis infections in allo-HCT patients.
  • Widespread prevalence of micafungin heteroresistance was observed across global isolates of C. parapsilosis.
  • Standard susceptibility assays failed to detect micafungin heteroresistance, highlighting a critical diagnostic gap.

Conclusions:

  • Heteroresistance in Candida parapsilosis explains previously unexplained micafungin prophylaxis failures in allo-HCT recipients.
  • A machine learning framework offers a promising tool for rapid and accurate detection of micafungin heteroresistance.
  • This diagnostic approach has the potential to guide clinical decision-making and improve patient care in high-risk populations.

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K